New Deuruxolitinib Data Show It Meets 'The Need for Speed'

Deuruxolitinib resulted in significant hair regrowth starting at Week 8, continually improving through Week 24, and the 8-mg and 12-mg BID doses showed significant efficacy vs placebo across subgroups, according to new data presented at the 2025 Fall Clinical Dermatology Conference.

Other highlights from the posters, which were based on a pooled analysis  of the THRIVE-AA1 and THRIVE-AA2 phase 3 trials, included that patients receiving deuruxolitinib achieved scalp hair regrowth as early as Week 8 (Severity of Alopecia Tool [SALT] 20) and Week 12 (SALT 10) with continuous improvements through Week 24.

In totality, the data demonstrated that patients using deuruxolitinib saw visible progress, fast. 

“The No. 1 thing is the need for speed: rapid and meaningful regrowth in patients with severe alopecia areata, and some of them reach their target of 80% scalp coverage in 8 weeks,” said clinical investigator Natasha Atanaskova Mesinkovska, MD, PhD. “The second thing is it just changes the conversation around alopecia areata, because it's a true step forward toward precision medicine. What does that mean for this medication? There's a test, CYP2C9, that is required prior to prescribing the medication, in order to identify people who would be poor metabolizers of this medication. You will not put those people on the medication. You are targeting who will tolerate the drug better, which is important.”  

Additionally, Sun Pharma Sun Pharma announced that it conducted a landmark survey—the first of its kind in the US—to better understand the gaps between healthcare providers and patients living with alopecia areata. The findings reveal important disconnects in how the disease is perceived and managed.

“Clinicians prioritize rapid and nearly complete hair regrowth in AA treatment and report high patient satisfaction with oral JAKis,” the authors wrote. “Despite this, only half believe their patients are aware of JAKi options. Our findings highlight an opportunity for improved patient education and shared decision-making.”